Revised secondary reagents guidance will address IVD performance criteria -- FDA's Gutman.
This article was originally published in The Gray Sheet
Executive Summary
IVD SECONDARY REAGENT GUIDANCE REVISIONS TO BE COMPLETED in the next several weeks, FDA staffers say. The changes seek to clarify two provisions of the June 1996 guidance, Steve Gutman, director of the Division of Clinical Laboratory Devices in FDA's Center for Devices and Radiological Health, said Sept. 8 at the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
You may also be interested in...
Replacement reagents
Updated 1Replacement Reagent & Instrument Family Policy Guidance notes that manufacturers "no longer need to submit an add-to-file prior to marketing different reagent/instrument combinations (including new family members) when both have been previously cleared." The December document, which includes replace reagent and instrument terminology and discusses CLIA categorization and special 510(k)s, supersedes a June 1996 guidance (2"The Gray Sheet" Sept. 15, 1997, I&W-4)...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.